September 21, 2022 7:53am

No active aftermarket to prognosticate from …

Indications: I feel Negative Indications and 1 Pump/Promote (BSTG – the usual suspect)

News: Verve Therapeutics (VERV -$0.52 or -1.46% pre-open) announced the clearance of its Clinical Trial Authorization (CTA) application by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for VERVE-101 as a potential treatment for patients with heterozygous familial hypercholesterolemia (HeFH). HeFH is a prevalent and potentially life-threatening genetic subtype of atherosclerotic cardiovascular disease (ASCVD) characterized by extremely high blood levels of disease-driving low-density lipoprotein cholesterol (LDL-C).

The cell and gene therapy sector shows more signs of downside movement alternating to continued weakness.

No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.27% or (+83 points), S&P futures are UP +0.21% (+8 points) and NASDAQ futures are DOWN -0.01% (-2 points) early in the pre-open – so far,


Stock futures rise slightly ahead of the Federal Reserve’s expected interest rate hike,

European stocks inch higher

Asia Pacific markets are lower ahead of the Fed’s rate hike



Indexes slid and pared their losses in the final hour on Tuesday as the Fed kicked off its September policy meeting and stocks braced for another large rate hike due out Wednesday.

The Dow closed DOWN -313.45 points (-1.01%) the S&P closed DOWN -43.96 points (-1.13%) while the Nasdaq closed down -109.97 points (-0.95%)

Economic Data Docket: the central bank will probably deliver its third consecutive 0.75 percentage point rate hike to tame high inflation. Also, existing home sales will also be released.


RegMed Investors’ (RMi) closing bell: “a slasher session ass good news becomes bad news.” …


Ebb and flow:

Q3/22 – September – 1 holiday, 7 positive and 6 negative closes

•             August – 1 neutral, 11 positive and 11 negative closes

•             July - 1 holiday, 10 negative and 10 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

I am abstaining from commenting other than my usual suspect …

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$0.10 with 9,718 shares traded after Friday’s +$1.19 with 2,660 shares traded, Thursday’s -$0.19 with 717 shares traded, Wednesday’s +$0.15 with 2,101 shares traded, Tuesday’s -$0.30 with 500 shares traded and last Monday’s -$0.10 with 442 shares traded <3-month average = 1,806>,

Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?

  • How many non-citizens of Chinese nationality are employed at BSTG – 3 managers/directors of 5 and 3 of 5 board directors?
  • Who and WHAT are funding the “spikes” in volume and share price?
  • What is DST Capital?  Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG?  Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
  • Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?


The BOTTOM LINE: The Fed policy announcement will hurt some portfolios no matter what it does:  as I had been writing, it's a time for investors to have minimal exposure.

Especially with another quarter about to close … and back to earnings season!

I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!

When a cell and gene therapy sector equity sells-off to or below a buy point, investors face a tough decision: hold tight, exit or trim the position. There's not necessarily a "right" answer. Sometimes the stock will bounce right back, others will keep falling — perhaps after briefly bouncing. A more-cautious approach may make more sense in the current volatile market.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash? Start by looking at cell and gene therapy companies trading below cash!” 

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”

That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.